Paper Details

  1. Home
  2. Paper Details

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.

Author: FinkelsteinJoel S, GoodeMelissa, LeeHang, McGovernFrancis J, SmithMatthew R, ZietmanAnthony L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared the effects of leuprolide and bicalutamide on bone mineral density and body composition in men with prostate cancer. The study found that bicalutamide increased bone mineral density and lessened fat accumulation. It also had fewer bothersome side effects than leuprolide.
Paper Details　
Original Abstract of the Article :
PURPOSE: Gonadotropin-releasing hormone agonists decrease bone mineral density, lean mass, and muscle size and increase fat mass in men with prostate cancer. Less is known about the effects of bicalutamide monotherapy on bone mineral density and body composition. PATIENTS AND METHODS: In a 12-month...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15226323

データ提供：米国国立医学図書館（NLM）

Bone Health and Body Composition: Comparing Bicalutamide and Leuprolide in Prostate Cancer Treatment

The treatment of prostate cancer often involves medications that can impact bone health and body composition. This research compares the effects of bicalutamide and leuprolide, two commonly used medications for prostate cancer, on bone mineral density and body composition. The study investigates the potential benefits and drawbacks of each medication in terms of bone health and overall well-being.

A Bone-Healthy Alternative: Bicalutamide Offers Potential Benefits for Prostate Cancer Patients

The study's findings suggest that bicalutamide monotherapy may offer a bone-health advantage over leuprolide monotherapy in men with prostate cancer. Bicalutamide was associated with an increase in bone mineral density, while leuprolide led to a decrease. This observation has significant implications for managing bone health in men undergoing prostate cancer treatment, potentially mitigating the risk of osteoporosis and fractures.

Beyond Bone Health: Considering the Broader Impact on Body Composition and Side Effects

While the study highlights the positive effects of bicalutamide on bone mineral density, it is important to consider the broader impact on body composition and potential side effects. While both medications can lead to changes in body composition, bicalutamide may offer a more favorable profile in terms of fat accumulation and side effects. It is essential to discuss the potential benefits and drawbacks of each medication with a healthcare professional to make informed decisions about treatment.

Dr.Camel's Conclusion

This study provides valuable insights into the impact of different prostate cancer treatments on bone health and body composition. Bicalutamide appears to offer a potential advantage in terms of bone mineral density, but it is crucial to consider the broader impact on body composition and potential side effects. A comprehensive discussion with a healthcare professional is essential to make informed decisions about treatment based on individual needs and preferences.

Date :
  1. Date Completed 2004-09-03
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

15226323

DOI: Digital Object Identifier

22/13/2546

Related Literature

Article Analysis
・Effects of bicalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.